These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35708896)

  • 1. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
    Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
    Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
    Ganesa S; Sule A; Sundaram RK; Bindra RS
    Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
    Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
    Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
    Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
    Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
    Liu IH; Ford JM; Kunz PL
    Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
    Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
    Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
    Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G
    Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
    Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
    Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEN1 Deficiency-Driven Activation of the β-Catenin-MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance.
    Xu J; Lou X; Wang F; Zhang W; Xu X; Ye Z; Zhuo Q; Wang Y; Jing D; Fan G; Chen X; Zhang Y; Zhou C; Chen J; Qin Y; Yu X; Ji S
    Adv Sci (Weinh); 2024 Sep; 11(35):e2308417. PubMed ID: 39041891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
    von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
    Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
    Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
    Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
    McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
    Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of expression of DNA mismatch repair proteins is rare in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T; Sapp HL; Rayson D; Barnes PJ; Drewniak M; Nassar BA; Huang WY
    Arch Pathol Lab Med; 2011 Dec; 135(12):1539-44. PubMed ID: 22129180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
    Oliver JA; Ortiz R; Jimenez-Luna C; Cabeza L; Perazzoli G; Caba O; Mesas C; Melguizo C; Prados J
    J Biosci; 2020; 45():. PubMed ID: 33097678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer.
    Ling ZQ; Li P; Ge MH; Hu FJ; Fang XH; Dong ZM; Mao WM
    Dig Dis Sci; 2011 Oct; 56(10):2992-3004. PubMed ID: 21674174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.